文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

辛伐他汀联合利福昔明治疗失代偿期肝硬化:一项随机临床试验

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在失代偿期肝硬化患者中,标准治疗加用辛伐他汀20 mg/d联合利福昔明1200 mg/d未改善结局,且治疗组有3例(2.6%)发生横纹肌溶解。

这项双盲、安慰剂对照的3期试验在14家欧洲医院纳入237例失代偿期肝硬化患者(Child-Pugh B级194例、C级43例),随机接受辛伐他汀20 mg/d联合利福昔明1200 mg/d(n=117)或外观相同的安慰剂(n=120),疗程12个月,均加用标准治疗。主要终点为符合慢加急性肝衰竭标准的肝硬化严重并发症发生率,治疗组21例(17.9%)vs 安慰剂组17例(14.2%)(HR 1.23,95%CI 0.65-2.34,P=0.52)。移植或死亡、肝硬化并发症复合终点两组均无差异。不良事件发生率相似,但治疗组3例(2.6%)发生横纹肌溶解。结论认为加用辛伐他汀联合利福昔明未改善失代偿期肝硬化患者结局。

要点

  • 失代偿期肝硬化患者标准治疗加用辛伐他汀20 mg/d联合利福昔明1200 mg/d,慢加急性肝衰竭发生率21例(17.9%)vs 安慰剂组17例(14.2%),HR 1.23(95%CI 0.65-2.34),P=0.52,无差异。
  • 移植或死亡:治疗组22例(18.8%)vs 安慰剂组29例(24.2%),HR 0.75(95%CI 0.43-1.32),P=0.32,无差异。
  • 肝硬化并发症复合终点(腹水、肝性脑病、静脉曲张出血、急性肾损伤、感染):治疗组50例(42.7%)vs 安慰剂组55例(45.8%),HR 0.93(95%CI 0.63-1.36),P=0.70,无差异。
  • 不良事件总数两组相似(426 vs 419,P=0.59),但治疗组3例(2.6%)发生横纹肌溶解。
  • 该3期试验结论:辛伐他汀联合利福昔明加用于标准治疗未改善失代偿期肝硬化患者结局。

适用人群与场景

  • 14家欧洲医院收治的失代偿期肝硬化患者,随机分组237例(Child-Pugh B级194例,C级43例),72%为男性,平均年龄57岁。

处置流程与药物剂量

  • 辛伐他汀20 mg/d联合利福昔明1200 mg/d,口服,疗程12个月,加用标准治疗,按Child-Pugh B级或C级分层随机。
  • 对照组使用外观相同的安慰剂,同样加用标准治疗,疗程12个月。

红旗征与不能漏的情况

  • 治疗组3例(2.6%)发生横纹肌溶解。

研究设计与关键结果

  • 研究设计:双盲、安慰剂对照、3期随机临床试验,2019年1月至2022年12月在14家欧洲医院开展,末次随访时间为2022年12月,随机237例(治疗组n=117,安慰剂组n=120)。
  • 主要终点:符合慢加急性肝衰竭标准的肝硬化严重并发症发生率,治疗组21例(17.9%)vs 安慰剂组17例(14.2%),HR 1.23(95%CI 0.65-2.34),P=0.52。
  • 次要终点移植或死亡:治疗组22例(18.8%)vs 安慰剂组29例(24.2%),HR 0.75(95%CI 0.43-1.32),P=0.32。
  • 次要终点肝硬化并发症复合终点(腹水、肝性脑病、静脉曲张出血、急性肾损伤、感染):治疗组50例(42.7%)vs 安慰剂组55例(45.8%),HR 0.93(95%CI 0.63-1.36),P=0.70。
  • 不良事件:治疗组426例次 vs 安慰剂组419例次,P=0.59;治疗组3例(2.6%)发生横纹肌溶解。

证据类型、等级与局限

  • 证据类型:双盲、安慰剂对照、3期随机临床试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在失代偿期肝硬化患者中,标准治疗加用辛伐他汀20 mg/d联合利福昔明1200 mg/d未改善慢加急性肝衰竭发生率、移植或死亡、肝硬化并发症复合终点,且治疗组有3例(2.6%)发生横纹肌溶解。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov Identifier: NCT03780673。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.

OBJECTIVE: To assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis.

DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.

INTERVENTIONS: Patients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C.

MAIN OUTCOMES AND MEASURES: The primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection).

RESULTS: Among the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis.

CONCLUSIONS AND RELEVANCE: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03780673.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pose E, Jiménez C, Zaccherini G, et al. Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial. JAMA. 2025. PMID: 39908052. doi:10.1001/jama.2024.27441

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。